← All organizations
Highest phase reached
Phase 3
First clinical trial
Nov 2, 1999First marketed drug
Aug 26, 1998First NDA
Aug 26, 1998Last known activity
Jan 31, 2026
Timeline
1980s
- Jan 1, 1989
Ionis Pharmaceuticals, Inc.— Founded
1990s
- Apr 30, 1999
aciclovir— Marketing Organization
2010s
- Oct 5, 2018
inotersen— NDA Organization
2020s
- Sep 15, 2020
Akcea Therapeutics— Acquired
Drugs by trial phase (71 distinct, 145 trials)
Phase 3 (12 own, 4 via acquisition)
Phase 2 (37 own, 4 via acquisition)
Phase 1 (10 own, 4 via acquisition)
Indications
Studied for
- Acromegaly
- Acute Disease
- Alzheimer Disease
- Amyloid Neuropathies
- Amyloid Neuropathies, Familial
- Amyloidosis
- Amyotrophic Lateral Sclerosis
- Angioedema
- Angioedemas, Hereditary
- Arthritis
- Arthritis, Rheumatoid
- Atrial Fibrillation
- Atrophy
- beta-Thalassemia
- Bronchitis
- Bronchitis, Chronic
- Carcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Non-Small-Cell Lung
- Cardiomyopathies
- Cardiovascular Abnormalities
- Cardiovascular Diseases
- Colitis
- Colitis, Ulcerative
- Congenital Abnormalities
- Coronary Artery Disease
- Coronary Disease
- Crohn Disease
- Cystic Fibrosis
- Cytomegalovirus Retinitis
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Disease
- Dyslipidemias
- Fatty Liver
- Fibrosis
- Genetic Diseases, Inborn
- Geographic Atrophy
- Glomerulonephritis, IGA
- Heart Diseases
- Hepatitis
- Hepatitis A
- Hepatitis B
- Hepatitis B, Chronic
- Hepatitis C
- Hepatitis C, Chronic
- Huntington Disease
- Hypercholesterolemia
- Hyperlipidemias
- Hyperlipoproteinemias
- Hyperlipoproteinemia Type I
- Hyperlipoproteinemia Type II
- Hypertension
- Hypertriglyceridemia
- Hypobetalipoproteinemias
- Hypolipoproteinemias
- Infant, Newborn, Diseases
- Insulin Resistance
- Kidney Diseases
- Kidney Failure, Chronic
- Lipid Metabolism Disorders
- Lipid Metabolism, Inborn Errors
- Lipodystrophy
- Lipodystrophy, Familial Partial
- Liver Diseases
- Lung Diseases
- Lung Diseases, Obstructive
- Lung Neoplasms
- Macular Degeneration
- Metabolic Diseases
- Metabolism, Inborn Errors
- Migraine Disorders
- Motor Neuron Disease
- Multiple Myeloma
- Myocardial Ischemia
- Myotonic Dystrophy
- Neoplasms
- Neoplasms, Plasma Cell
- Non-alcoholic Fatty Liver Disease
- Obesity
- Pancreatic Neoplasms
- Parkinson Disease
- Polyneuropathies
- Prostatic Neoplasms
- Pulmonary Disease, Chronic Obstructive
- Renal Insufficiency
- Retinitis
- Sclerosis
- Syndrome
- Thalassemia
- Thromboembolism
- Ulcer
- Venous Thromboembolism
Marketed drugs (13)
Subsidiaries (1 direct, 1 total across the full acquisition tree)
Recent trials (50)
- NCT06415448Lead sponsorN/A—
- NCT06360237Lead sponsorN/A—
- NCT03400098Lead sponsorN/A—
- NCT07298447Lead sponsorPhase 3Jan 31, 2026
- NCT06914609Lead sponsorPhase 3Jun 10, 2025
- NCT06673069Lead sponsorPhase 1Nov 30, 2024
- NCT06430385Lead sponsorPhase 1/Phase 2Oct 31, 2024
- NCT06150716Lead sponsorPhase 1Mar 31, 2024
- NCT06153966Lead sponsorPhase 1/Phase 2Dec 31, 2023
- NCT05681351Lead sponsorPhase 3Dec 13, 2022
- NCT05667493Lead sponsorPhase 3Nov 30, 2022
- NCT05610280Lead sponsorPhase 3Nov 21, 2022
- NCT05579860Lead sponsorPhase 1Oct 5, 2022
- NCT05552326Lead sponsorPhase 3Aug 31, 2022
- NCT05392114Lead sponsorPhase 3Jul 13, 2022
Details
- Founded
- Carlsbad, CA, US Jan 1, 1989
- First NDA
- Aug 26, 1998
- Last known activity
- Jan 31, 2026
Designations held
- Orphan drug
- Fast track
- Priority review
- Breakthrough therapy
Notes
--- Notes from Hepasense: No evidence still extant ---